2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Sunday, November 10, 2019

9:00AM-11:00AM: Abstract Number: 372

Periaortitis and Coronary Arteritis in IgG4-Related Disease: Eastern Mediterranean Experience

Miscellaneous Rheumatic & Inflammatory Disease Poster I: Fibroinflammatory & Granulomatous Disorders & Therapies

9:00AM-11:00AM: Abstract Number: 663

Peripheral Blood Toll Like Receptor 7 Expression and Serum Interferon Lambda 1 Levels in Systemic Lupus Erythematosus and Their Relation to Disease Activity and Lupus Nephritis

SLE – Clinical Poster I: Epidemiology & Pathogenesis

9:00AM-11:00AM: Abstract Number: 617

Peripheral Involvement Is Associated with Less Radiographic Spinal Progression in Patients with Early Axial Spondyloarthritis: Results from the German Spondyloarthritis Inception Cohort

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster I: Axial Spondyloarthritis, Clinical Features

9:00AM-11:00AM: Abstract Number: 671

Peripheral Nervous System Disease in Systemic Lupus Erythematosus: Results from an International, Inception Cohort Study

SLE – Clinical Poster I: Epidemiology & Pathogenesis

9:00AM-11:00AM: Abstract Number: 451

Persistent and Non-Articular Regional and Widespread Pain Are Common in Early Rheumatoid Arthritis, Impacting Remission Rates and Reflected in Patient Global Scores

RA – Diagnosis, Manifestations, & Outcomes Poster I: Risk Factors, Predictors, & Prognosis

9:00AM-11:00AM: Abstract Number: 114

Persistent Synovial Resident Memory T Cells Mediate Arthritis Flares

T Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster

9:00AM-11:00AM: Abstract Number: 530

Phase I Evaluation of the PDE4 Inhibitor LY2775240: Head to Head Comparison with Apremilast Using an Ex Vivo Pharmacodynamic Assay

RA – Treatments Poster I: Novel Treatments

9:00AM-11:00AM: Abstract Number: 48

Phenotype-based Clustering Along with Analysis of Molecular Profile Might Help to Define Precise CV-risk Profiles in RA Patients

RA – Etiology & Pathogenesis Poster I

9:00AM-11:00AM: Abstract Number: 118

Polymorphonuclear Neutrophils and Regulatory T Lymphocytes (Treg) Cooperate to Sustain Treg Activity but This Interaction Is Altered in Rheumatoid Arthritis Patients

T Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster

9:00AM-11:00AM: Abstract Number: 759

Polymyalgia Rheumatica Patients with and Without Elevated Baseline Acute Phase Reactants: Distinct Subgroups of Polymyalgia Rheumatica?

Vasculitis – Non-ANCA-Associated & Related Disorders Poster I: Takayasu's Arteritis & Polymyalgia Rheumatica

9:00AM-11:00AM: Abstract Number: 742

Polymyalgia Rheumatica: New Therapeutic Strategy Based on Low Dose Metrotexate Plus Local Infiltration with Corticosteroids

Vasculitis – Non-ANCA-Associated & Related Disorders Poster I: Takayasu's Arteritis & Polymyalgia Rheumatica

9:00AM-11:00AM: Abstract Number: 761

Polymyalgia Rheumatica: Winter Is Coming

Vasculitis – Non-ANCA-Associated & Related Disorders Poster I: Takayasu's Arteritis & Polymyalgia Rheumatica

9:00AM-11:00AM: Abstract Number: 436

Poor Concordance Between Remission Judged by Physicians and a Patient-Acceptable Symptom State in Psoriatic Arthritis

Patient Outcomes, Preferences, & Attitudes Poster I: Patient Reported Outcomes

9:00AM-11:00AM: Abstract Number: 73

Potent Anti-neutrophil Properties of the Natural Compound 6-Gingerol in Models of Lupus and Antiphospholipid Syndrome

SLE – Animal Models Poster

9:00AM-11:00AM: Abstract Number: 649

Potentially Reversible Associations with Fatigue in SLE Patients – Results from a Single-centre Study

SLE – Clinical Poster I: Epidemiology & Pathogenesis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].